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Background: The expression and functional role of CysLT2 receptors in asthma have not been clariﬁed. In
this study, we evaluated CysLT2 receptors expression, and effects of CysLT2-and CysLT1/2-receptor an-
tagonists on antigen-induced bronchoconstriction using isolated lung tissues from both asthma and non-
asthma subjects.
Methods: CysLT1 and CysLT2 receptors expression in asthma and non-asthma lung tissue preparations
was examined in immunohistochemistry experiments, and their functional roles in antigen-induced
bronchoconstriction were assessed using ONO-6950, a dual CysLT1/2-receptor antagonist, montelukast,
a CysLT1 receptor antagonist, and BayCysLT2RA, a CysLT2 receptor-speciﬁc antagonist.
Results: CysLT1 receptors were expressed on the bronchial smooth muscle and epithelium, and on
alveolar leukocytes in 5 in 5 non-asthma subjects and 2 in 2 asthma subjects. On the other hand,
although degrees of CysLT2 receptors expression were variable among the 5 non-asthma subjects, the
expression in the asthma lung was detected on bronchial smooth muscle, epithelium and alveolar leu-
kocytes in 2 in 2 asthma subjects. In the non-asthma specimens, antagonism of CysLT2 receptors did not
affect antigen-induced bronchial contractions, even after pretreatment with the CysLT1-receptor speciﬁc
antagonist, montelukast. However, in the bronchus isolated from one of the 2 asthma subjects, antag-
onism of CysLT2 receptors suppressed contractions, and dual antagonism of CysLT1 and CysLT2 receptors
resulted in additive inhibitory effect on anaphylactic contractions.
Conclusions: CysLT2 receptors were expressed in lung specimens isolated from asthma subjects. Acti-
vation of CysLT2 receptors may contribute to antigen-induced bronchoconstriction in certain asthma
population.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cysteinyl leukotrienes (CysLTs), LTC4, LTD4 and LTE4, are in-
ﬂammatory mediators derived from the 5-lipoxygenase pathway
of arachidonic acid metabolism.1 As these mediators are known to
be deeply involved in bronchial asthma via activation of the CysLT1armacology, Faculty of Phar-
aotoge-cho, Hirakata, Osaka
abe).
ety of Allergology.
rgology. Production and hosting by Elsereceptor,2e4 selective antagonists of this receptor, including
pranlukast,5,6 montelukast,7 and zaﬁrlukast8 have widely been
used as therapeutic agents for bronchial asthma. On the other
hand, a number of studies have cloned and characterized another
receptor subtype of CysLTs termed CysLT2 receptor.9e11 This re-
ceptor, like the CysLT1 receptor,12 is a G-protein-coupled receptor
with an amino acid sequence 38% identical to that of the CysLT1
receptor.9 CysLT2 receptor mRNA has been detected in a number of
human organ and tissues, including lung macrophages, airway
smooth muscles, and peripheral blood leukocytes,9 and its
expression has been identiﬁed on the mucus gland and nasal
mucosal epithelium of patients with chronic rhinosinusitis, or
allergic nasal vascular smooth muscles.13,14 As for endogenousvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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man CysLT1 receptors is LTD4 > LTC4 ¼ LTE4, while that for CysLT2
receptors is LTC4 ¼ LTD4 > LTE4,10 Based on these ﬁndings, it is
expected that the CysLT2 receptor is involved in the pathophysi-
ology of bronchial asthma. However, it is unclear where CysLT2
receptors are histologically expressed in airway tissues of asthma
subjects.
It is well known that CysLTs exert potent contractile action on
human bronchial smooth muscles through activation of CysLT1
receptors. Indeed, in vitro antigen-induced contraction of passively
sensitized human bronchial tissue is markedly suppressed by a pre-
treatment with CysLT1 receptor antagonists.4,15,16 However,
although CysLT2 receptors are also expressed in bronchial smooth
muscles,9 their functional role in bronchial contraction has not
been clariﬁed. In this study, we evaluated CysLT receptors expres-
sion and effects of ONO-6950, dual CysLT1/2 antagonists and Bay-
CysLT2RA,17 a CysLT2 receptor-speciﬁc antagonist on antigen-
induced bronchoconstriction using isolated lung tissues from
both asthma and non-asthma subjects.
Methods
Subjects
Macroscopic normal portions of lung tissue were obtained from
21 non-asthma and 2 asthma subjects (Table 1) during lung cancer
surgery at Ogaki Municipal Hospital (Ogaki, Japan). All subjects
provided their informed consents for use of the collected materials
in medical research under a protocol approved by the Ethical
Committees of Ogaki Municipal Hospital and Kyoto Pharmaceutical
University (Kyoto, Japan). Both asthma subjects were diagnosed
with bronchial asthma at Ogaki Municipal Hospital in 2003. As
shown in Table 1, asthma subject 1 and 2 were treated with inhaled
corticosteroid (ICS)/long-acting b2 receptor agonist (LABA) (ﬂuti-
casone/salmeterol, Adoair®) at medium (250 mg, twice a day) and
low (250 mg, once a day) doses, respectively. In addition, the asthma
subject 1 had been treated with montelukast (Singulair®) for
approximately 3 months from a day of approximately 1 year before
the surgery.Table 1
Background of lung tissue donors.
Non-asthma
subjects
Asthma
subject 1
Asthma
subject 2
Age, yr 66.1 ± 12.5 62 60
Age at asthma onset (yr) 54 52
Gender 18 male/3 female Female Female
ICS/LABA
(Fluticasone/salmeterol,
Adoair®)
Yes (medium
dose)
Yes
(low dose)
FEV1 (% predicted) 90.3 87.4
Peripheral blood leukocytes
(cells/ml)
8440 3920
Neutrophils (%) 39.7 49.7
Eosinophils (%) 6.8 1.0
Basophils (%) 1.2 1.3
Monocytes (%) 5.1 4.1
Lymphocytes (%) 47.2 43.9
Platelets (cells/ml) 319000 201000
Total serum IgE (IU/ml) 838 Not detected
Smoker No Yes
In asthma subject 1, Adoair® therapy (250 mg, twice a day) had been continued until
the lung cancer surgery, and the lung function and hematological data were
collected approximately 6 months before and 1 week after the surgery, respectively.
In asthma subject 2, Adoair® therapy (250 mg, once a day) had been continued until 2
years after the surgery when the lung function and hematological data were
collected.How the collected lung samples were used for various experi-
ments is summarized in our online supplementary material
(Supplementary Table 1).
Histological and immunohistochemical studies
The lung tissues were ﬁxed in 10% formaldehyde, embedded in
parafﬁn wax, and cut into 4 (4-mm thick) serial sections. Two of
these sections were stained ﬁrst with hematoxylin and eosin (HE),
and thenwith alcian blue/periodic acid-Schiff (AB/PAS). The other 2
sections were used in immunohistochemistry for detection of
CysLT1 and CysLT2 receptors expression. After antigenicity activa-
tion, the sections were treated with 3% hydrogen peroxide solution,
washed with 50 mM TriseHCl buffer (pH 7.4), and blocked with 1%
bovine serum albumin. The sections were then stained with rabbit
polyclonal anti-human CysLT1 receptor antibody (LS-A1317, Life-
Span Biosciences, Seattle, WA, USA at a dilution of 1:600) or with
rabbit polyclonal anti-human CysLT2 receptor antibody (120560,
Cayman Chemical, Ann Arbor, MI, USA at a dilution of 1:300) over-
night at room temperature. After washing with 50 mM TriseHCl
buffer (pH 7.4), the sections were treated with anti-rabbit bio-
tinylated secondary antibody for 30min at 4 C,washedwith 50mM
TriseHCl buffer (pH 7.4) once again, and stained with streptavidin-
horseradish peroxidase for 30min. Coloring was then developed by
soaking the sections in 3,30-diaminobenzidine solution for 10 min,
followed by counterstaining with a hematoxylin solution.
CysLT receptor antagonists
Montelukast, a CysLT1 receptor antagonist, BayCysLT2RA,17
a CysLT2 receptor antagonist, and ONO-6950, a dual CysLT1/2 re-
ceptor antagonist, were synthesized in Ono Pharmaceutical Co., Ltd.
(Osaka, Japan) and used in this study as CysLT receptor antagonists.
The chemical formula of ONO-6950 is 4,4’-[4-ﬂuoro-7-(2-{4-[4-
(3-ﬂuoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-
indole-1,3-diyl]dibutanoic acid.
LTD4-induced intracellular calcium mobilization
Human CysLT1 (hCysLT1) receptor- and human CysLT2 (hCysLT2)
receptor-expressing cells were generated by transfecting each
expression vector into Chinese hamster ovary (CHO)-K1 cells as
described in Supplementary Methods.
Calcium mobilization assays were carried out using Fura-2 AM-
loaded CHO-K1 cells stably expressing hCysLT1 or hCysLT2 receptor.
The cells were cultured in Ham's F-12 medium (Invitrogen, Carls-
bad, CA, USA) containing 10% fetal bovine serum and 0.5 mg/ml
geneticin (Invitrogen) in 5% CO2 at 37 C. The cells were seeded into
96-well special optics ﬂat clear bottom black polystyrene TC-
treated microplates (Corning, Corning, NY, USA) at 3  104 cells/
well and then incubated in 5% CO2 for 24 h at 37 C. The cells were
treatedwith 5 mMFura-2 AM (Dojindo, Kumamoto, Japan) in Hanks'
Balanced Salt Solution (HBSS) containing 20mMHEPES and 2.5mM
probenecid (SigmaeAldrich, St. Louis, MO USA) for 1 h at 37 C.
After washing with HBSS containing 20 mM HEPES, various con-
centrations of montelukast, BayCysLT2RA, ONO-6950 or vehicle
(0.1% DMSO) were added to the cells, and the cells were incubated,
protected from light, for another 30 min at room temperature.
LTD4 (100 nM for hCysLT1 and 0.3 nM for hCysLT2 receptor) was
next added to the cells, and intracellular calcium mobilization was
determined by the ratio of ﬂuorescence intensity (f340/f380)
measured at 500 nm every 3 s for 4.5 min using a Functional Drug
Screening System (FDSS 3000, Hamamatsu Photonics, Hamamatsu,
Japan).
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strips
As described in our previous report,15 bronchi (outer diameter
2e6 mm) were isolated from macroscopic normal portions of the
lung tissue and cut into 1.5 mmwide spirals. In the experiments for
evaluation of the effects of CysLT antagonists on antigen-induced
contraction, the bronchi were passively sensitized by incubation
in human atopic serum (RAST score¼ 4<) for 2 h at 37 C. Bronchial
strips (2 cm long, outer diameter 2e4 mm) were then cut and
suspended under an isotonic resting tension of 300 mg at 37 C in a
Magnus bath containing Tyrode's solution gassed with 95% O2e5%
CO2. Before starting the experiments, acetylcholine (5 mM) and then
histamine (10 mM) were repeatedly applied to the preparations
until almost equal contractions were obtained.
When the resting tonus of the histamine-treated washed
smooth muscle had stabilized, guinea pig serum albumin (Sig-
maeAldrich) at ﬁnal concentration of 0.1 or 1 mg/ml was addedFig. 1. Immunohistochemical micrographs of lung tissues from the 5 non-asthma subjects. T
with hematoxylin and eosin (HE), and then with alcian blue/periodic acid-Schiff (AB/PAS). Th
CysLT2 receptors expression. Arrows show representative immunoreactive sites for each reto prevent adsorption of ONO-6950 and montelukast to the inner
wall of the Magnus bath. Just after addition of guinea pig serum
albumin, ONO-6950 (100, 300 or 1000 nM), BayCysLT2RA (100 or
300 nM), montelukast (30 or 100 nM), or DMSO (ﬁnal concen-
tration: 0.1%) was applied. Antigen (mite extract from Dermato-
phagoides farinae: 3 mg/ml) or LTD4 (30 nM) challenge was
initiated 30e35 min after treatment with each CysLT antagonist.
As previously reported,2,18 a cyclooxygenase inhibitor, indo-
methacin (SigmaeAldrich, 3 mM) and an anti-histamine drug,
pyrilamine (SigmaeAldrich, 1 mM) were applied 10 and 5 min
before antigen challenge, respectively, to make antigen-induced
contractile response dependent on CysLTs activity. Data,
expressed as % of 10 mM histamine-induced contraction, were
then calculated using height 30 min before the challenge as
baseline.
In experiments using LTD4 as a smooth muscle constrictor,
passive sensitization of bronchial tissue was not performed, and
neither indomethacin nor pyrilamine was used.he tissues were cut into 4 serial sections (4-mm thick). Two of the sections were stained
e other two sections were used in immunohistochemical determination of CysLT1 and
ceptor.
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Immunohistochemical detection of CysLT1 and CysLT2 receptors
As shown in Figure 1, the specimens isolated from all 5 non-
asthma subjects revealed CysLT1-receptor immunoreactivity in
the bronchial epithelium, bronchial smooth muscle layer, and
alveolar leukocytes, although the degree of this receptor's
expression was relatively low in subject 2. On the other hand,
CysLT2 receptors were expressed predominantly on the bronchial
epithelium of non-asthma subjects. CysLT2 receptors expression
on bronchial smooth muscle was observed in non-asthma subject
4 and 5, and that on alveolar leukocytes was in non-asthma sub-
ject 1, 4 and 5 (Fig. 1).
Like the specimens from the 5 non-asthma subjects, specimens
from the 2 asthma subjects showed expression of CysLT1 receptor
on the bronchial smoothmuscle, bronchial epithelium, and alveolar
leukocytes (Fig. 2). Regarding CysLT2 receptors as well, specimens
from both 2 asthma subjects showed the expression on the bron-
chial smoothmuscle, bronchial epithelium, and alveolar leukocytes
(Fig. 2). In addition, CysLT2 receptor-positive sites were detected in
mucus including leukocytes, which may have been released in the
bronchial lumen of the 2 asthma subjects.
When asthma lung tissues were stained with rabbit IgG in place
of anti-CysLT1 or anti-CysLT2 receptor antibody, no immunostaining
sites were detected as shown in Supplementary Figure 1.Fig. 2. Immunohistochemical micrographs of lung tissues from the 2 asthma subjects. The ti
hematoxylin and eosin (HE), and thenwith alcian blue/periodic acid-Schiff (AB/PAS). The oth
receptors expression. Arrows show representative immunoreactive sites for each receptor.Effects of CysLT receptor antagonists on LTD4-induced intracellular
calcium mobilization in CysLT1 or CysLT2 receptor-expressing cells
ONO-6950 inhibited both CysLT1 and CysLT2 receptors-
mediated response in LTD4-induced calcium mobilization assay
with IC50 values of 1.7 and 25 nM, respectively (Table 2). This in-
hibition was less than that of montelukast for CysLT1 receptor-
mediated response (IC50 value of 0.46 nM), but comparable to
that reported for BayCysLT2RA against CysLT2 receptor-mediated
response (IC50 value of 14 nM).17 Montelukast showed very weak
inhibition of CysLT2 receptor-mediated response (IC50 value of
1800 nM), while BayCysLT2RA inhibition of CysLT1 receptor-
mediated response is reported to be even weaker (IC50 value of
2500 nM).17Effects of CysLT receptor antagonists on LTD4- or antigen-induced
bronchial smooth muscle contractions
As shown in Figure 3A, ONO-6950 concentration-dependently
inhibited LTD4-induced contractions in the bronchi isolated from
non-asthma subjects with almost complete inhibition at 1000 nM
(Fig. 3A). This effect was comparable to that of montelukast
(100 nM), suggesting that ONO-6950 antagonistic activity for the
CysLT1 receptor is approximately 10-fold less than that of mon-
telukast. As for BayCysLT2RA, this CysLT2 receptor antagonist atssues were cut into 4 serial sections (4-mm thick). Two of the sections were stained with
er two sections were used in immunohistochemical determination of CysLT1 and CysLT2
Fig. 3. (A) Effects of ONO-6950 and montelukast on LTD4-induced contractions in
bronchi isolated from non-asthma subjects. ONO-6950 (100, 300 and 1000 nM),
montelukast (100 nM) or vehicle (0.1% DMSO) was added 30 min before addition of
LTD4 (30 nM). Each point represents the mean or mean ± S.E. of 2e4 experiments. (B)
Effect of BayCysLT2RA on LTD4-induced contractions in bronchi isolated from non-
asthma subjects. BayCysLT2RA (300 nM) or vehicle (0.1% DMSO) was added 30 min
before addition of LTD4 (30 nM). Each point represents the mean ± S.E. of 8
experiments.
Table 2
ONO-6950 and montelukast IC50 values for inhibition of LTD4-induced intracellular
calcium mobilization response in human CysLT1 receptor- or human CysLT2
receptor-expressing cells.
IC50 value (nM)
CysLT1 receptor CysLT2 receptor
ONO-6950 1.7 (1.2e2.4) 25 (19e32)
Montelukast 0.46 (0.37e0.58) 1800 (1500e2100)
Fura 2-AM-loaded CHO-K1 cells expressing human CysLT1 or human CysLT2 re-
ceptor were stimulated with LTD4 at 100 nM, for CysLT1 receptors, or LTD4 at 0.3 nM,
for CysLT2 receptors. IC50 values and 95% conﬁdence intervals shown in parentheses
were estimated from a 2-parameter logistic model using the results of 5 experi-
ments. The cells, treated with CysLT receptor antagonists, were incubated for 30min
before LTD4 addition.
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isolated from the non-asthma subjects (Fig. 3B).
Figure 4 represents effects on antigen-induced contraction of
bronchi isolated from non-asthma subjects. Both ONO-6950
(300 nM) and montelukast (30 nM) clearly, but only partially,
inhibited antigen-induced bronchial smooth muscle contractions,
especially 30e90 min after antigen challenge (Fig. 4). BayCysLT2RA
(100 nM), on the other hand, had no inhibitory or potentiating ef-
fect on such contractions, even at the high concentration of
1000 nM (data not shown). When the CysLT2 receptor-speciﬁc
antagonist BayCysLT2RA was used in combination with mon-
telukast, it neither potentiated norweakenedmontelukast-induced
inhibition of antigen-induced bronchial smooth muscle contrac-
tions (Fig. 4).
In the bronchi isolated from the asthma subject 1, both the
CysLT1-speciﬁc antagonist montelukast and the CysLT2-speciﬁc
antagonist BayCysLT2RA, partially inhibited antigen-induced
airway smooth muscle contractions (Fig. 5A, Supplementary
Fig. 2A). Interestingly, combination of montelukast and BayCysL-
T2RA produced additive strong inhibition of such contractions
(Fig. 5A, Supplementary Fig. 2A). Consistent with this ﬁnding, the
dual CysLT1/2 antagonist ONO-6950 inhibited antigen-induced
airway smooth muscle contractions with a potency equivalent to
that of montelukast and BayCysLT2RA combination treatment
(Fig. 5A, Supplementary Fig. 2A). It is noteworthy to mention here
that the baseline of montelukast-treated bronchus was relatively
high at antigen challenge, probably due to unstable baseline during
pre-treatment with montelukast, pyrilamine and indomethacin
(Fig. 5A, Supplementary Fig. 2A).
As for the bronchi isolated from the asthma subject 2, only
preparations treated with antagonists of the CysLT1 receptor
(montelukast or ONO-6950) showed reduced contractions (Fig. 5B,
Supplementary Fig. 2B).
Discussion
In the present study, we showed that CysLT1 receptors were
expressed on the bronchial smooth muscle and epithelium, and on
alveolar leukocytes in all non-asthma and asthma subjects. On the
other hand, CysLT2 receptors were expressed on these airway cells
in 2 in 2 asthma subjects, whereas theywere detected in only a part
of non-asthma subjects. Furthermore, our results show that
blockage of CysLT2 receptors suppressed antigen-induced bronchial
smoothmuscle contractions in lung tissue preparations from one of
the two asthma subjects.
One of the limitations of our study is that we were only able to
use 2 asthma samples. It is quite difﬁcult to obtain sufﬁcient lung
tissues from asthma patients for research. However, it should be
noted that we used serial tissue sections that allowed co-expression of CysLT2 and CysLT1 receptors at the same sites. To
our knowledge, this is the ﬁrst report demonstrating the concur-
rent expression of CysLT2 receptors with CysLT1 receptors in airway
tissues of actual asthma subjects compared to non-asthma subjects.
In addition, our ﬁndings suggest that CysLT2 receptors are func-
tionally involved in asthma bronchoconstriction.
It is also interesting to note that the asthma subjects recruited in
this study had mild symptoms compared to those of the so-called
“severe asthma”, since asthma subject 1 and 2 were classiﬁed as
“mild persistent” and “mild intermittent”, and were treated with a
medium dose ICS (treatment step 2) and a low dose ICS (treatment
step 1), respectively. It may therefore be speculated that expression
of CysLT2 receptors is further up-regulated in subjects with severe
asthma or asthma exacerbation. Indeed, it is reported that asthma
exacerbation triggers CysLT2 receptors expression in eosinophils, a
phenomenon not observed during stable periods.19 On the other
hand, Negri et al.20 have demonstrated that ﬂuticasone inhibited IL-
Fig. 4. Effects of ONO-6950, montelukast, BayCysLT2RA, and combination of mon-
telukast and BayCysLT2RA on mite antigen-induced contractions in bronchi isolated
from the non-asthma subjects. The bronchi were passively sensitized with atopic
serum before being suspended in Magnus bath. ONO-6950 (300 nM), montelukast
(30 nM), BayCysLT2RA (100 nM) or vehicle (0.1% DMSO) was added 30 min before
antigen challenge. A cyclooxygenase inhibitor, indomethacin and an anti-histamine
drug, pyrilamine were applied 10 and 5 min before antigen challenge, respectively,
to make antigen-induced contractile response as much as possible dependent on
CysLTs activity. Each point represents the mean ± S.E. of 4 or 5 experiments.
Fig. 5. Effects of ONO-6950, montelukast, BayCysLT2RA, and combination of mon-
telukast and BayCysLT2RA on mite antigen-induced contractions in bronchi isolated
from the 2 asthma subjects (A: Subject 1; B: Subject 2). The experimental procedure is
the same as that given in the legend of Fig. 4. Each point represents the value obtained
in each experiment.
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ceptors, on monocytes, T cells, and eosinophils. Because the asthma
subjects were treated with ICS/LABA, the CysLT2 receptors expres-
sion may had been negatively regulated. Regarding effect of LABA
on CysLT receptors expression, there has been no study to our
knowledge.
In agreement with our results showing the presence of CysLT2
receptors in alveolar leukocytes, both CysLT1 and CysLT2 receptors
have been reported to be expressed not only in macrophages,9 but
also in eosinophils,19,21 mast cells,22 basophils,23 and dendritic
cells.24 The functional importance of CysLT2 receptors in these
leukocytes was not addressed in this study. However, Jiang et al.22
have shown that both CysLT1 and CysLT2 receptors are expressed on
the membranes and nuclei of a human mast cell line, and that
knockdown of CysLT2 receptors increases CysLT1 receptors surface
expression. These ﬁndings suggest that activation of CysLT2 re-
ceptors down-regulates CysLT1 receptors expression.
In addition to CysLT2 receptors activation negative feedback on
CysLT1 receptors expression, a broader functional regulation be-
tween CysLT1 and CysLT2 receptors has also been reported:
Knockdown of CysLT2 receptors was reported to increase CysLT1
receptor-dependent proliferation of human mast cells.22 Barrett
et al.24 have shown that D. farinae sensitization and challenge in
CysLT2 receptor-deﬁcient mice results in a marked increase in
eosinophilic pulmonary inﬂammation, serum IgE level, and Th2
cytokine level. Maekawa et al.25 have also reported that
leukotriene-induced ear edema shows a delayed peak response in
CysLT2 receptor-deﬁcient mice compared to wild-type mice. These
ﬁndings suggest that activation of CysLT2 receptors down-regulates
not only CysLT1 receptors expression, but also CysLT1 receptor-
mediated biological and inﬂammatory responses. However, as
shown in this study, treatment with the CysLT2 receptor antagonist
BayCysLT2RA did not reverse montelukast-induced inhibition of
anaphylactic bronchoconstriction in specimens from both the non-
asthma and asthma subjects. Therefore, CysLT1 receptors activation
may be differently regulated by CysLT2 receptors expression, atleast in human bronchial contractions. Alternatively, the observed
discrepancy may be due to species difference.
It is now widely known that blockade of CysLT1 receptors
strongly inhibits antigen-induced bronchial contractions in speci-
mens isolated from non-asthma subjects. However, this blockade is
not complete as shown in the present study and in other litera-
ture.4,15,16 The results of the current study suggest that CysLT2 re-
ceptors activation has no signiﬁcant role in the bronchial
contractions recorded in the non-asthma specimens. On the other
hand, in one of the two asthma specimens, CysLT2 receptors
blockade inhibited anaphylactic bronchoconstriction. This inhibi-
tion was potentiated by dual blockade of CysLT1 and CysLT2 re-
ceptors. These results suggest that there may be a certain asthma
background, in which activation of CysLT2 receptors is involved in
anaphylactic bronchocontractile response, and thus may play a
signiﬁcant role in asthma response in certain asthma population.
It is not clear why the involvement of CysLT2 receptor activation
in anaphylactic response was different between the 2 asthma
specimens, even though CysLT2 receptors were expressed in both
specimens to a similar degree. Mechanisms other than increased
T. Sekioka et al. / Allergology International 64 (2015) 351e358 357expression of CysLT2 receptors, such as functional up-regulation,
may also be involved in this response. It is intriguing to speculate
that asthma background affects such functional up-regulation. On
the other hand, it should be noted that one lung sample showing
CysLT2 receptors contribution to bronchoconstriction was derived
from an asthma subject (asthma subject 1), who had had a history
of atopy, whereas the other subject (asthma subject 2) had not. In
addition, asthma subject 1 had a relatively high percentage of eo-
sinophils in peripheral blood leukocytes (6.8%). Moreover, asthma
subject 1 was non-smoker, whereas asthma subject 2 was smoker.
It is therefore suggested that these subjects backgrounds may have
affected the function of CysLT2 receptors. However, further studies
are needed to clarify the exact role of CysLT2 receptors in asthma
pathogenesis.
Henderson et al.26 have demonstrated that montelukast
blockade of CysLT1 receptors improves airway remodeling,
including airway goblet cell metaplasia, smooth muscle cell layer
thickening, and subepithelial ﬁbrosis in a mouse model of asthma.
The histological ﬁndings of this study revealed a thickened bron-
chial epithelium exhibiting epithelial cells ﬁlled with AB/PAS-
positive mucus in the specimens prepared from the asthma pa-
tients. Interestingly, in these specimens, CysLT1 receptors tended to
be expressed on the mucus-positive epithelium, suggesting that
CysLT1 receptors activation is involved in the development of
epithelial remodeling in humans as reported in mice.26 It has also
been reported that CysLTs mediate Th2 cell-dependent pulmonary
inﬂammation through activation of CysLT1 receptors in mice.27,28
Considering the fact that both CysLT2 and CysLT1 receptors are
highly expressed in the airway epithelium, it is possible that CysLT2
receptors also play a role in the development of airway remodeling.
This hypothesis need to be further investigated both in vitro and
in vivo.
In conclusion, we have shown in this study that CysLT2 receptors
were expressed in lung specimens isolated from 2 asthma subjects.
This CysLT2 receptors expression may contribute to antigen-
induced bronchoconstriction in certain asthma cases. These re-
sults imply that CysLT2 receptor antagonists, including BayCysL-
T2RA and ONO-6950, may be useful for the treatment of the certain
asthma population. However, because the present ﬁndings were
led from only 2 asthma specimens, further preclinical and clinical
studies on CysLT2-or CysLT1/2-receptor antagonists are required.
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